REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Condition:   Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB) Intervention:   Drug: chlormethine gel Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

In conclusion, cdTSE has a limited role in SS. TTNT is reduced in heavily pre-treated MF patients, suggesting greater benefit when utilized earlier in treatment sequencing.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSIONS: These findings demonstrate that LDRT can eradicate malignant T cells in MF, provides robust disease control, and is associated with improved survival in high-risk early stage patients. PMID: 31636100 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared to vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T-cells. PMID: 31615932 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Clinical and laboratory diagnostics of mycosis fungoides (MF), the most common cutaneous lymphoma is challenging. Our previous work described 4 promising markers of S ézary syndrome (SS): T-plastin, Twist, NKp46 and KIR3DL2 (Michel et al. 2013). Tox has been shown to be an additional marker for MF and SS. The aim of the present study was to confirm this combination of blood-derived markers in a validation cohort of SS, erythodermic and earlier MF for improving d iagnosis and predicting prognosis. Patients with a confirmed diagnosis of MF or SS and patients with other skin diseases were included.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Melanoma and Other Skin Cancers Source Type: research
Cutaneous T-cell lymphomas, CTCLs, comprise a group of malignancies largely represented by two subtypes, mycosis fungoides (MF) and S ézary syndrome (SS). The incidence of CTCL has increased appreciably since the 1970’s, but the pathogenesis is poorly understood. Recent studies have demonstrated clustering of CTCL patient in several geographic areas suggesting that environmental factors may play a role in CTCL pathogenesis. A r etrospective chart review was conducted using the STAT data set from the Florida Cancer Data System registry.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Introduction: Thiazides (TZ) have been reported to be associated with an increased risk for both malignant melanoma (MM) and keratinocyte cancers (BCC and SCC). Moreover, although an association between TZ and the most common subtypes: mycosis fungoides (MF) and S ézary syndrome (SS) has previously been reported, there have been no large population studies reporting data for such an association with CTCL overall. The aim of this study is to explore the association between all CTCL and chronic TZ exposure in a large “real world-setting” database: the Nort hwestern Medicine Enterprise Data Warehouse (NMEDW...
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, has a dismal prognosis in advanced stages. The success of immune checkpoint inhibitors (ICI) in treating advanced malignancies has not extended to MF. There is an urgent need to identify predictive biomarkers, and to advance immunotherapies in MF. Neoantigens are ‘new’ peptides, generated by somatic mutations in tumour cells, that evoke an immune response. As tumour-specific markers, neoantigens are an attractive immunotherapeutic target.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research
More News: Cancer | Cancer & Oncology | Cutaneous T cell lymphoma | Drugs & Pharmacology | Lymphoma | Mycosis Fungoides | Research | Skin | Study | T-cell Lymphoma